Life Sciences

Riptide Therapeutics

The University of Chicago

Riptide Therapeutics is working to develop a new, first-in-class, targeted covalent inhibitor (TCI) of telomerase reverse transcriptase (TERT).

This company will be presenting on Day 2 of DeepTechU 2022. View schedule >>